Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation

Netherlands Journal of Medicine

Volumn 75, Issue 2, 2017, Pages 65-73

  Sari, V ^a   Atiqi, R ^b   Hoorn, E J ^a   Heijboer, A C ^c   Van Gelder, T ^a   Hesselink, D A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Ferric carboxymaltose; Fibroblast growth factor (FGF) 23; Hypophosphataemia; Iron; Kidney transplantation; Phosphate

Indexed keywords

ACENOCOUMAROL; ALFACALCIDOL; AMLODIPINE; CALCITRIOL; COLECALCIFEROL; COTRIMOXAZOLE; CREATININE; ESOMEPRAZOLE; FERRIC CARBOXYMALTOSE; FERROUS GLUCONATE; FIBROBLAST GROWTH FACTOR 23; MYCOPHENOLATE MOFETIL; PARATHYROID HORMONE; PREDNISOLONE; TACROLIMUS; FERRIC ION; FIBROBLAST GROWTH FACTOR; MALTOSE; PHOSPHATE;

ADULT; AGED; ARTICLE; BIOCHEMICAL ANALYSIS; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; HYPERPARATHYROIDISM; HYPOPHOSPHATEMIA; IRON DEFICIENCY ANEMIA; IRON THERAPY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; PHOSPHATE URINE LEVEL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; VERY ELDERLY; YOUNG ADULT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; CASE REPORT; CHEMICALLY INDUCED; GENETICS; METABOLISM; POSTOPERATIVE COMPLICATION;

ADULT; AGED; FEMALE; FERRIC COMPOUNDS; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOPHOSPHATEMIA; KIDNEY TRANSPLANTATION; MALE; MALTOSE; PHOSPHATES; POSTOPERATIVE COMPLICATIONS;

EID: 85014954966     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose. A review of its use in iron-deficiency anaemia. Drugs. 2009;69:739-56.
2. Moore RA, Gaskell H, Rose P. Meta-analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord. 2011;11:4.
3. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372:1832-43.
4. Barish CF, Koch T, Butcher A. Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized, controlled trails. Anemia. doi:10.1155/2012/172104. [published online ahead of print Sept 10, 2012]
5. Sato K, Shiraki M. Saccharated ferric oxide-induced osteomalacia in Japan: Iron-induced osteopathy due to nephropathy. Endocr J. 1998;45:431-9.
6. Schouten BJ, Doogue MP, Soule SG. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009;46:167-9.
7. Malone M, Barish C, He A. Comparative review of the safety and efficacy of ferric carboxymaltose versus standard medical care for the treatment of iron deficiency anemia in bariatric and gastric surgery patients. Obes Surg. 2013;23:1413-20.
8. Onken JE, Bregman DB, Harrington RA, et al. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014;54:306-15.
9. Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28:1793-803.
10. Schouten BJ, Hunt PJ, Livesey JH. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study. J Clin Endocrinol Metab. 2009;94:2332-7.
11. Van Wyck DB, Mangione A, Morrison J. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49:2719-28.
12. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-92.
13. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370-8.
14. Vervloet MG, Larsson TE. Fibroblast growth factor-23 and Klotho in chronic kidney disease. Kidney Int Suppl. 2011;1:130-5.
15. Bhan I, Shah A, Holmes J, et al. Post-transplant hypophosphatemia: tertiary ‘hyper- phosphatoninism’? Kidney Int. 2006;70:1486-94.
16. Block GA, Lx JH, Ketteler M, et al. Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis. 2013;62:457-73.
17. Onken JE, Bergman DB, Harrinton RA, et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2014;29:833-42.
18. Prats M, Font R, García C. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study. BMC Nephrol. 2013;14:167.
19. Qunibi WY, Martinez C, Smith M. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non- dialysis- dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26:1599-607.
20. Evenepoel P, Meijers BKI, de Jonge H, et al. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation. Clin J Am Soc Nephrol. 2008;3:1829-36.
21. Mani LY, Nseir G, Venetz JP. Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient. Transplantation. 2010;90:804-5.
22. Blazevic A, Hunze J, Boots JMM. Severe hypophosphataemia after intravenous iron administration. Neth J Med. 2014;72:49-53.
23. Fossati P, Prencipe L. Berti G. Enzymic creatinine assay: a new colorimetric method based on hydrogen peroxide measurement. Clin Chem. 1983;29:1494-6.
24. Katewa SD, Katyare SS. A simplified method for inorganic phosphate determination and its application for phosphate analysis in enzyme assays. Anal Biochem. 2003;323:180-7.
25. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-12.
26. Jüppner H, Potts JT. Immunoassays for the detection of parathyroid hormone. J Bone Miner Res. 2002;17:N81-6.
27. Goodman WG. The evolution of assays for parathyroid hormone. Semin Dial. 2005;18:296-301.
28. Iqbal SJ. Vitamin D metabolism and the clinical aspects of measuring metabolites. Ann Clin Biochem. 1994;31:109-24.
29. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol. 2009;19:73-8
30. Heijboer AC, Levitus M, Vervloet MG, et al. Determination of fibroblast growth factor 23. Ann Clin Biocherm. 2009;46:338-40.
31. Evenepoel P, Naesens N, Claes K. Tertiary ‘hyperphosphatoninism’ accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant. 2007;7:1193-200.
32. Shimizu Y, Tada Y, Yamauchi M, et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone. 2009;45:814-6.
33. Charytan C, Bernardo MV, Koch TA. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active- controled, multi- center study. Nephrol Dial Transplant. 2013;28:953-64.
34. Bhattacharyya N, Chong WH, Gafni RI. Fibroblast growth factor 23: State of the field and future directions. Trends Endocrinol Metab. 2012;23:610-8.
35. Wolf M, White KE. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens. 2014;23:411-9.
36. Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29:2075-84.
37. Felsenfeld AJ, Gutman RA, Drezner M. Hypophosphatemia in long-term renal transplant recipients: effects on bone histology and 1,25- dihydroxy-cholecalciferol. Miner Electrolyte Metab. 1986;12:333-41.
38. Ghanekar H, Welch BJ, Moe OW. Post- renal transplantation hypophosphatemia: a review and novel insights. Curr Opin Nephrol Hypertens. 2006;15:97-104.
39. Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab. 2005;90:2456-65.
40. Weisinger JR, Carlini RG, Rojas E. Bone disease after renal transplantation. Clin J Am Soc Nephrol. 2006;1:1300-13.
41. Seeherungvong W, Wolf M. Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation. Pediatr Transplant. 2011;15:37-46.